Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
$40.17
<$0.01(<0.01%)
At close: 4:00 PM EST
$40.17
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.26 - $46.67
Previous CloseN/A
Volume97.81K
Average Volume (3M)1.97M
Market Cap
$3.49B
Enterprise Value$3.44B
Total Cash (Recent Filing)$157.50M
Total Debt (Recent Filing)$199.18M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Mar 12, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding86,995,480
10 Day Avg. Volume1,728,740
30 Day Avg. Volume1,968,807
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)11.98
Price to Sales (P/S)66.13
P/FCF Ratio-9.41
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue49.67
Enterprise Value/Gross Profit55.56
Enterprise Value/Ebitda-34.91
Forecast
1Y Price Target
$46.75Price Target Upside16.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial ReceptionAnalyst highlights that Yutrepia's higher-than-expected prescriptions, patient starts, and an expanding prescriber base indicate commercial momentum that can drive market share gains in pulmonary hypertension.
Late-stage Pipeline AdvancementThe randomized, placebo-controlled Re-Spire Phase 3 program for L606, designed to include patients on common antifibrotic treatments, establishes a regulatory pathway that could extend long-term revenue beyond the current product.
Salesforce ExpansionManagement's planned salesforce expansion to broaden physician coverage in target disease areas should improve market penetration and support sustained Yutrepia uptake.
Bears Say
Clinical Timeline UncertaintyUnclear timing of data readouts from planned open-label and pivotal studies increases uncertainty about when clinical results will act as meaningful stock catalysts.
Demand VariabilitySeasonal and specialty-pharmacy ordering patterns can create variability in patient starts and prescription flows, reducing near-term sales visibility and raising short-term stock volatility.
Patent Litigation RiskPending and imminent patent litigation introduces legal and commercial risk that could delay market access, raise costs, or limit revenue realization.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $11.26 and its highest was $46.67 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.49B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Mar 12, 2026 which is in 26 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Nov 03, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.389 by $0.349.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.19.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 86,995,480 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.389. Following the earnings report the stock price went up 3.53%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$46.75 (16.38% Upside)
$46.75 (16.38% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
169.20%
12-Months-Change
Fundamentals
Return on Equity
-183.82%
Trailing 12-Months
Asset Growth
9.13%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Liquidia has experienced a strong launch and financial performance with YUTREPIA, achieving significant prescription uptake and positive cash flow. However, the ongoing net loss and litigation uncertainty present challenges that could impact future performance.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$46.75
▲(16.38% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
22.66% Insiders
7.35% Mutual Funds
0.21% Other Institutional Investors
60.24% Public Companies and Individual Investors